Shares of Solventum Corp. shed 4.42% to $79.75 Friday, on what proved to be an all-around positive trading session for the ...

The addition of Solventum’s business provides a strategic fit with Thermo Fisher and will create value for customers, according to Marc N. Casper, chairman, president, and CEO of Thermo Fisher.

Solventum surpassed fourth-quarter revenue and earnings expectations while facing challenges in segments and regulatory ...

Solventum (NYSE:SOLV) yesterday announced fourth-quarter results that came in ahead of the consensus forecast on Wall Street.

Wells Fargo raised the firm’s price target on Solventum (SOLV) to $75 from $73 and keeps an Equal Weight rating on the shares. The Q4 beat was ...

Piper Sandler raised the firm’s price target on Solventum (SOLV) to $84 from $75 and keeps a Neutral rating on the shares. The firm notes ...

ST. PAUL, Minn. - Solventum Corporation (NYSE: SOLV) reported fourth-quarter earnings that fell short of analyst expectations, sending shares down 2% in after-hours trading. The healthcare technology ...

M spin-off Solventum forecast annual profit above analyst estimates on Thursday, betting on strong sales of its wound care and surgical sterilization products.

The Maplewood, Minnesota-based company said it had net income of 17 cents per share. Earnings, adjusted for one-time gains and costs, were $1.41 per share. The results topped Wall Street expectations.

The acquisition of Solventum’s Purification & Filtration business will allow Thermo Fisher Scientific to enhance its ...

Thermo Fisher Scientific Inc. (Waltham, Mass.) announced that the company has entered into a definitive agreement with Solventum  to acquire Solventum’s ...